Each year, we are required under the Workplace Safety and Insurance Act (WSIA) to have an external firm review the cost, efficiency, and effectiveness of one of our programs through a value-for-money audit. The latest audit focused on our drug benefit program and was conducted by KPMG.
Findings
The report outlined recommendations in five key areas: legislative and policy framework, program governance, service delivery and case management, strategic procurement and partnerships, and billing and payment.
We will use the recommendations to guide future business planning and make sure we continue to strengthen the drug benefit program and the services we provide to customers.